- Home
- NBTX vs SCPH Comparison
NBTX vs SCPH Comparison
Compare NBTX & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- SCPH
- Stock Information
- Founded
- NBTX 2003
- SCPH 2013
- Country
- NBTX France
- SCPH United States
- Employees
- NBTX N/A
- SCPH N/A
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- NBTX Health Care
- SCPH Health Care
- Exchange
- NBTX Nasdaq
- SCPH Nasdaq
- Market Cap
- NBTX 211.9M
- SCPH 173.6M
- IPO Year
- NBTX 2020
- SCPH 2017
- Fundamental
- Price
- NBTX $9.85
- SCPH $5.52
- Analyst Decision
- NBTX Strong Buy
- SCPH Strong Buy
- Analyst Count
- NBTX 1
- SCPH 3
- Target Price
- NBTX $8.00
- SCPH $15.00
- AVG Volume (30 Days)
- NBTX 15.0K
- SCPH 1.1M
- Earning Date
- NBTX 09-17-2025
- SCPH 08-07-2025
- Dividend Yield
- NBTX N/A
- SCPH N/A
- EPS Growth
- NBTX N/A
- SCPH N/A
- EPS
- NBTX N/A
- SCPH N/A
- Revenue
- NBTX N/A
- SCPH $49,969,000.00
- Revenue This Year
- NBTX N/A
- SCPH $108.95
- Revenue Next Year
- NBTX $74.67
- SCPH $78.30
- P/E Ratio
- NBTX N/A
- SCPH N/A
- Revenue Growth
- NBTX N/A
- SCPH 107.79
- 52 Week Low
- NBTX $2.76
- SCPH $1.94
- 52 Week High
- NBTX $10.59
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- NBTX 75.73
- SCPH 62.53
- Support Level
- NBTX $8.20
- SCPH $4.33
- Resistance Level
- NBTX $10.59
- SCPH $4.82
- Average True Range (ATR)
- NBTX 0.51
- SCPH 0.35
- MACD
- NBTX 0.18
- SCPH -0.01
- Stochastic Oscillator
- NBTX 79.95
- SCPH 93.28
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.